贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液临床研究

目的探讨贝伐单抗联合顺铂胸膜腔内灌注对非小细胞肺癌恶性胸腔积液的临床疗效及毒副反应。方法将2011年1月至2015年1月解放军180医院收治的94例伴有恶性胸腔积液的非小细胞肺癌患者随机分为对照组和观察组,每组各47例。观察组患者给予贝伐单抗联合顺铂胸膜腔内灌注,对照组给予顺铂胸膜腔内灌注。观察并比较两组患者临床疗效及毒副反应发生情况。结果观察组治疗有效率(70.2%)高于对照组(44.7%),两组比较,差异有统计学意义(P<0.05)。毒副反应中,观察组的恶心呕吐及皮疹的发生率低于对照组,差异有统计学意义(P<0.05)。结论贝伐单抗联合顺铂胸膜腔内灌注治疗非小细胞肺癌恶性胸腔积液能取得较好疗效,且毒副反应发生率较低,值得临床推广。

Clinical analysis of bevacizumab combined with cisplatin in treatment of malignant pleural effusion in patients with non-small cell lung cancer

Objective To explore the clinical efficacy and adverse reaction of intrapleural therapy combined with bevacizumab and cisplatin in treatment of malignant pleural effusion in patients with non-small cell lung cancer(NSCLC). Methods A total of 94 cases of NSCLC patients with malignant pleural effusion received in No. 180 Hospital of PLA from January 2011 to January 2015. Patients were randomly divided into the observation group and the control group,with 47 cases in each group. Patients in the observation group received intrapleural bevacizumab combined with cisplatin,while,the control group received intrapleural cisplatin alone. The clinical efficacy and adverse reaction were investigated and compared. Results The effective treatment rate in the observation group was sig-nificantly higher than that in the control group(70. 2% versus 44. 7% ,P < 0. 05). The incidence of adverse reaction such as postoper-ative nausea,emesis and rash in the observation group was less than that in the control group,the difference was statistically significant (P < 0. 05). Conclusion The application of intrapleural therapy combined with bevacizumab and cisplatin in treatment of malignant pleural effusion in patients with NSCLC can achieve better therapeutic effect with lower adverse reaction. It is worth of clinical promotion.